Profile data is unavailable for this security.
About the company
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
- Revenue in USD (TTM)299.91m
- Net income in USD-84.58m
- Incorporated2021
- Employees756.00
- LocationProcept Biorobotics Corp150 Baytech DriveSAN JOSE 95134United StatesUSA
- Phone+1 (650) 232-9832
- Fax+1 (302) 636-5454
- Websitehttps://www.procept-biorobotics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enovis Corp | 2.23bn | -1.37bn | 1.29bn | 7.37k | -- | 0.6388 | -- | 0.578 | -24.20 | -24.20 | 39.35 | 35.33 | 0.4474 | 1.56 | 5.37 | 303,144.60 | -27.38 | -3.14 | -30.81 | -3.56 | 57.19 | 52.01 | -61.19 | -9.77 | 1.16 | 0.0495 | 0.4018 | -- | 23.46 | -8.73 | -1,423.10 | -- | 7.58 | -- |
| Tandem Diabetes Care Inc | 1.01bn | -203.37m | 1.32bn | 2.65k | -- | 9.96 | -- | 1.32 | -3.05 | -3.05 | 15.08 | 1.96 | 1.10 | 3.25 | 8.64 | 380,000.40 | -22.20 | -10.11 | -30.80 | -12.33 | 53.23 | 51.67 | -20.20 | -11.71 | 1.90 | -9.88 | 0.7028 | -- | 25.74 | 21.01 | 56.86 | -- | 27.42 | -- |
| Conmed Corp | 1.37bn | 47.06m | 1.33bn | 3.90k | 28.25 | -- | 10.92 | 0.9641 | 1.52 | 1.52 | 44.24 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.08 | 55.56 | 3.42 | 3.78 | -- | 3.24 | -- | -- | 5.18 | 9.77 | -64.47 | 37.66 | -- | -5.59 |
| Iradimed Corp | 80.51m | 21.18m | 1.34bn | 160.00 | 63.74 | 13.60 | 60.35 | 16.61 | 1.65 | 1.65 | 6.27 | 7.73 | 0.7706 | 1.61 | 6.65 | 503,195.40 | 20.28 | 14.28 | 22.52 | 15.97 | 77.07 | 76.58 | 26.31 | 22.27 | 5.72 | -- | 0.00 | 66.71 | 11.71 | 13.72 | 11.87 | 14.84 | 78.55 | -- |
| Adapthealth Corp | 3.26bn | 75.81m | 1.44bn | 10.50k | 19.16 | 0.8912 | 3.03 | 0.4427 | 0.5553 | 0.5553 | 23.90 | 11.94 | 0.7354 | 17.20 | 8.33 | 310,020.30 | 1.96 | -2.81 | 2.28 | -3.17 | 25.32 | 19.63 | 2.67 | -4.19 | 0.8584 | 2.30 | 0.5253 | -- | 1.90 | 43.84 | 112.19 | -- | 70.36 | -- |
| Kestra Medical Technologies Ltd | 74.26m | -138.79m | 1.59bn | 330.00 | -- | 8.56 | -- | 21.45 | -2.76 | -2.76 | 1.47 | 3.19 | 0.4034 | -- | 9.40 | 225,027.30 | -71.43 | -122.23 | -92.37 | -192.35 | 46.40 | -- | -177.06 | -342.51 | -- | -116.72 | 0.2033 | -- | 115.05 | -- | -25.08 | -- | 150.61 | -- |
| Pulse Biosciences Inc | 86.00k | -74.73m | 1.62bn | 75.00 | -- | 17.48 | -- | 18,848.84 | -1.14 | -1.14 | 0.0013 | 1.37 | 0.0009 | -- | -- | 1,146.67 | -74.06 | -83.75 | -80.63 | -94.40 | -224.42 | -- | -86,898.84 | -12,644.52 | 10.01 | -- | 0.00 | -- | -- | -- | -26.95 | -- | -27.12 | -- |
| Procept Biorobotics Corp | 299.91m | -84.58m | 1.67bn | 756.00 | -- | 4.40 | -- | 5.58 | -1.54 | -1.54 | 5.45 | 6.81 | 0.6772 | 1.81 | 3.91 | 396,702.40 | -19.10 | -26.94 | -21.74 | -29.81 | 64.55 | 54.37 | -28.20 | -83.14 | 7.20 | -- | 0.1194 | -- | 64.84 | 105.21 | 13.68 | -- | -10.34 | -- |
| AxoGen Inc | 214.71m | -2.10m | 1.73bn | 451.00 | -- | 13.17 | 356.46 | 8.06 | -0.0486 | -0.0486 | 4.56 | 2.62 | 1.05 | 1.55 | 7.75 | 476,073.20 | -1.03 | -11.36 | -1.17 | -13.05 | 74.76 | 78.42 | -0.9767 | -15.37 | 2.64 | 0.6493 | 0.2852 | -- | 17.81 | 11.91 | 54.12 | -- | -2.84 | -- |
| Omnicell Inc | 1.18bn | 2.05m | 1.75bn | 3.60k | 902.15 | 1.42 | 21.38 | 1.48 | 0.0432 | 0.0432 | 25.70 | 27.45 | 0.5786 | 7.19 | 5.01 | -- | 0.1002 | 0.7331 | 0.1357 | 0.9767 | 42.49 | 44.80 | 0.1732 | 1.32 | 1.22 | -- | 0.1198 | -- | 6.53 | 5.84 | -83.62 | -42.34 | 1.93 | -- |
| AtriCure Inc | 518.31m | -28.77m | 1.88bn | 1.30k | -- | 3.95 | -- | 3.63 | -0.608 | -0.608 | 10.90 | 9.59 | 0.829 | 1.68 | 8.79 | 398,696.20 | -4.60 | -3.84 | -5.24 | -4.25 | 74.87 | 74.53 | -5.55 | -7.13 | 2.85 | -17.96 | 0.1252 | -- | 16.55 | 15.05 | -46.85 | -- | 14.00 | -- |
| Artivion Inc | 422.65m | -9.12m | 1.91bn | 1.60k | -- | 4.36 | 137.94 | 4.52 | -0.242 | -0.242 | 9.48 | 9.26 | 0.509 | 1.72 | 5.16 | 264,153.80 | -1.10 | -2.47 | -1.29 | -2.66 | 64.50 | 65.02 | -2.16 | -5.89 | 2.88 | 1.29 | 0.3324 | -- | 9.75 | 7.06 | 56.37 | -- | 6.75 | -- |
| Inspire Medical Systems Inc | 882.62m | 44.56m | 1.98bn | 1.25k | 46.40 | 2.97 | 34.61 | 2.24 | 1.47 | 1.47 | 29.45 | 22.94 | 1.10 | 1.27 | 8.93 | 708,364.40 | 5.56 | -4.83 | 6.28 | -5.43 | 84.92 | 84.59 | 5.05 | -5.12 | 4.01 | -- | 0.00 | -- | 28.49 | 57.80 | 352.96 | -- | 70.20 | -- |
| Quidelortho Corp | 2.71bn | -1.18bn | 1.98bn | 6.60k | -- | 0.974 | -- | 0.731 | -17.38 | -17.38 | 40.11 | 29.99 | 0.4351 | 2.41 | 7.18 | 411,272.70 | -18.91 | 0.0044 | -22.09 | 0.005 | 47.15 | 59.13 | -43.45 | 0.009 | 0.9805 | 0.6537 | 0.5663 | 0.00 | -7.17 | 39.07 | -20,216.83 | -- | 48.27 | -- |
| LeMaitre Vascular Inc | 240.87m | 53.34m | 2.00bn | 651.00 | 38.56 | 5.27 | 31.37 | 8.29 | 2.28 | 2.28 | 10.35 | 16.71 | 0.494 | 1.03 | 7.45 | 369,993.80 | 10.94 | 9.09 | 11.69 | 9.89 | 70.97 | 66.24 | 22.14 | 16.64 | 11.45 | -- | 0.3077 | 38.38 | 13.63 | 13.40 | 46.28 | 19.68 | 13.11 | 15.91 |
| UFP Technologies Inc | 597.95m | 67.12m | 2.06bn | 4.15k | 31.07 | 5.11 | 24.02 | 3.45 | 8.61 | 8.61 | 76.71 | 52.37 | 0.9261 | 4.89 | 6.86 | 144,223.80 | 10.40 | 10.12 | 11.87 | 11.53 | 28.51 | 27.07 | 11.23 | 10.64 | 1.36 | 8.39 | 0.2657 | 0.00 | 26.08 | 20.52 | 31.29 | 24.46 | 10.82 | -- |
Data as of Feb 11 2026. Currency figures normalised to Procept Biorobotics Corp's reporting currency: US Dollar USD
52.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.89m | 14.12% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.74m | 8.48% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.73m | 6.67% |
| AllianceBernstein LPas of 30 Sep 2025 | 3.42m | 6.12% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 2.05m | 3.67% |
| Westfield Capital Management Co. LPas of 30 Sep 2025 | 1.97m | 3.53% |
| Mackenzie Financial Corp.as of 30 Sep 2025 | 1.45m | 2.60% |
| Champlain Investment Partners LLCas of 30 Sep 2025 | 1.44m | 2.57% |
| Artisan Partners LPas of 30 Sep 2025 | 1.37m | 2.44% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.32m | 2.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
